![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Chem. , 18 November 2022
Sec. Medicinal and Pharmaceutical Chemistry
Volume 10 - 2022 | https://doi.org/10.3389/fchem.2022.1082236
This article is a correction to:
Dual-Specificity Phosphatase CDC25B Was Inhibited by Natural Product HB-21 Through Covalently Binding to the Active Site
A Corrigendum on
Dual-specificity phosphatase CDC25B was inhibited by natural product HB-21 through covalently binding to the active site
by Zhang S, Jia Q, Gao Q, Fan X, Weng Y and Su Z (2018). Front. Chem. 6:531. doi: 10.3389/fchem.2018.00531
In the original article, there was an error in the affiliations as published, in which a third affiliation was wrongly included for author “Shoude Zhang”. The correct affiliations appear above.
In the original article, there was an error in Figure 6, page 4, as published. In the same batch of experiments, WB experiments for two compounds were done at the same time, and the article incorrectly used the results of another drug in the experiments. The corrected Figure 6 and its caption appear below.
FIGURE 6. Inhibition of CDK1 dephosphorylation caused by HB-21. The cells in the G2/M phase were treated with the indicated concentration of HB-21 or DMSO for 4 h, and then harvested. The samples were processed for Western blot analysis.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Cdc25B inhibitor, sesquiterpene lactone, anticancer, cell cycle progression, covalent binding to protein
Citation: Zhang S, Jia Q, Gao Q, Fan X, Weng Y and Su Z (2022) Corrigendum: Dual-specificity phosphatase CDC25B was inhibited by natural product HB-21 through covalently binding to the active site. Front. Chem. 10:1082236. doi: 10.3389/fchem.2022.1082236
Received: 31 October 2022; Accepted: 10 November 2022;
Published: 18 November 2022.
Edited and reviewed by:
Michael Kassiou, The University of Sydney, AustraliaCopyright © 2022 Zhang, Jia, Gao, Fan, Weng and Su. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shoude Zhang, c2hvdWRlLnpoYW5nQHFodS5lZHUuY24=; Zhanhai Su, c3V6aGFuaGFpQGZveG1haWwuY29t
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.